- Home
- BCTX vs CASI Comparison
BCTX vs CASI Comparison
Compare BCTX & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- CASI
- Stock Information
- Founded
- BCTX 2014
- CASI 1991
- Country
- BCTX Canada
- CASI China
- Employees
- BCTX N/A
- CASI N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- CASI Health Care
- Exchange
- BCTX Nasdaq
- CASI Nasdaq
- Market Cap
- BCTX 21.8M
- CASI 24.9M
- IPO Year
- BCTX N/A
- CASI 1996
- Fundamental
- Price
- BCTX $11.00
- CASI $1.44
- Analyst Decision
- BCTX Strong Buy
- CASI Strong Buy
- Analyst Count
- BCTX 1
- CASI 1
- Target Price
- BCTX $40.00
- CASI $4.00
- AVG Volume (30 Days)
- BCTX 89.1K
- CASI 46.6K
- Earning Date
- BCTX 10-16-2025
- CASI 11-28-2025
- Dividend Yield
- BCTX N/A
- CASI N/A
- EPS Growth
- BCTX N/A
- CASI N/A
- EPS
- BCTX N/A
- CASI N/A
- Revenue
- BCTX N/A
- CASI $31,564,000.00
- Revenue This Year
- BCTX N/A
- CASI N/A
- Revenue Next Year
- BCTX $380.95
- CASI N/A
- P/E Ratio
- BCTX N/A
- CASI N/A
- Revenue Growth
- BCTX N/A
- CASI 36.64
- 52 Week Low
- BCTX $6.00
- CASI $1.09
- 52 Week High
- BCTX $190.50
- CASI $6.30
- Technical
- Relative Strength Index (RSI)
- BCTX 45.44
- CASI 37.46
- Support Level
- BCTX $11.75
- CASI $1.35
- Resistance Level
- BCTX $13.43
- CASI $1.73
- Average True Range (ATR)
- BCTX 1.07
- CASI 0.16
- MACD
- BCTX -0.34
- CASI -0.04
- Stochastic Oscillator
- BCTX 6.12
- CASI 15.45
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.